SOURCE: SinoFresh Healthcare, Inc.

December 06, 2007 09:00 ET

SinoFresh Non-Antibiotic Nasal Spray Initial Experiments Show Product Has a Complete Killing Activity of MRSA "Super Bug"

SinoFresh Nasal and Sinus Care Human Clinical Trials Testing Efficacy in Eliminating Antibiotic Resistant MRSA From the Nasal Cavity

ENGLEWOOD, FL--(Marketwire - December 6, 2007) - SinoFresh HealthCare, Inc. (OTCBB: SFSH), developer of an over-the-counter nasal spray that kills bacteria and fungi, is pleased to announce up-coming human clinical trials to be conducted under the direction of the University of Chicago, School of Medicine. This study follows an earlier study conducted under the direction of Dr. Barry Kreisiwirth at the Public Health Research Institute at the International Center for Public Health whereas; the following conclusions were reported:

"These initial killing experiments using SinoFresh Nasal Spray each show virtual contact killing of the well characterized community acquired Methicillin"

"Resistant Staphylococcus Aureur strain MW2 had a complete killing activity within 30 seconds in the presence and absence of mucin and at a high bacterial concentrations."

SinoFresh CEO Charles Fust states: "We are pleased to see such profound interest emerging from the Medical Research community. Since the nasal passages are a known link in the infectious process of MRSA, I have been personally motivated over the years of SinoFresh Nasal and Sinus Care product development in determining if a new, non-antibiotic approach is feasible. The possibility of having a non-obtrusive, inexpensive preventative measure holds great potential. Based on pharmacologic mechanism of action of our compound, bacterial drug resistance is highly unlikely."

MRSA Background:

The annual cost in the US to treat hospitalized patients with methicillin resistant Staphylococcus aureus (MRSA) infections is estimated to be $3.2 billion to $4.2 billion, according to a new analysis presented at the annual meeting of the "International Society for Pharmacoeconomics and Outcomes Research" (ISPOR) in Washington, D.C. Prolonged hospital stays, including time spent in intensive care units, primarily drive the high costs of treating infections caused by MRSA, a serious, multi-drug resistant pathogen. Currently, the only topical drug product used to rid the nasal reservoir of bacteria is now beginning to show a lack of efficacy due to the emergence of resistant bacteria.

About SinoFresh HealthCare, Inc.

SinoFresh HealthCare, Inc. is a developer and marketer of therapies to treat inflammatory and infectious diseases of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms suspected of causing pathogenesis of the mouth, nose and throat. The Company holds certain patents and patent applications on its innovative pharmaceutical technology and relies upon a panel of medical experts and management team experienced in the bio-pharmaceutical industry.

The Company's product, SinoFresh™ Nasal & Sinus Care, is the only over-the-counter antiseptic nasal spray that kills bacteria and fungi and viral pathogens in the throat and nasal passages. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that affects many Americans annually. SinoFresh™ Nasal & Sinus Care is available nationwide in Rite Aid, CVS, Sav-On Drugs, Costco and other drug, grocery and mass merchandise retailers. More information is available at

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.

Contact Information